Palvella Therapeutics (PVLA) Equity Average (2016 - 2024)
Historic Equity Average for Palvella Therapeutics (PVLA) over the last 12 years, with Q3 2024 value amounting to -$84.1 million.
- Palvella Therapeutics' Equity Average fell 33691.98% to -$84.1 million in Q3 2024 from the same period last year, while for Sep 2024 it was -$84.1 million, marking a year-over-year decrease of 33691.98%. This contributed to the annual value of -$23.3 million for FY2023, which is 15916.58% down from last year.
- Latest data reveals that Palvella Therapeutics reported Equity Average of -$84.1 million as of Q3 2024, which was down 33691.98% from -$78.9 million recorded in Q2 2024.
- Palvella Therapeutics' 5-year Equity Average high stood at $52.3 million for Q4 2021, and its period low was -$84.1 million during Q3 2024.
- Over the past 5 years, Palvella Therapeutics' median Equity Average value was $37.4 million (recorded in 2020), while the average stood at $18.9 million.
- Per our database at Business Quant, Palvella Therapeutics' Equity Average soared by 12519.25% in 2020 and then plummeted by 44885.1% in 2024.
- Palvella Therapeutics' Equity Average (Quarter) stood at $37.4 million in 2020, then soared by 40.0% to $52.3 million in 2021, then crashed by 39.11% to $31.8 million in 2022, then crashed by 169.04% to -$22.0 million in 2023, then tumbled by 282.58% to -$84.1 million in 2024.
- Its last three reported values are -$84.1 million in Q3 2024, -$78.9 million for Q2 2024, and -$75.7 million during Q1 2024.